PHARMD PHD, co-founder & ceo
Cristiana Pires holds a degree in pharmaceutical sciences from University of Porto and a PhD in life sciences from NOVA Medical School, Portugal. During her graduate studies at Miguel Seabra’s laboratory she explored cellular reprogramming strategies to obtain retinal pigment epithelium cells (a specific population of retinal cells) for cell replacement therapy applications. On January 2016, Cristiana joined Filipe Pereira’s group interested in addressing new perspectives of reprogramming for the development of therapies to modulate immune responses. In 2018 she moved to Lund University where she continues the same line of research as a post-doctoral researcher. Additionally, Cristiana was appointed as CEO of Asgard Therapeutics AB. Now, by combining her pharmaceutical and scientific background with entrepreneurship experience, Cristiana is motivated to bring TrojanDC to the patients.